A biotech superstar with UNTHSC roots

By Jan Jarvis

ZS Pharma team

 

Six years ago in an acceleration lab at UNT Health Science Center, the co-founders of ZS Pharma were developing a drug that they believed held great promise. But even with such lofty expectations, ZS Pharma co-founders Alvaro Guillem and Jeff Keyser may have underestimated their biotech startup’s potential.

Earlier this month British drug maker AstraZeneca agreed to acquire ZS Pharma for $2.7 billion in cash.

In the pharmaceutical world – where it typically takes a decade or more to move a drug from bench to bedside – ZS Pharma has moved at lightning speed. UNT Health Science Center helped make it all possible by providing offices, conference rooms and a lab where much of the work was done, Guillem said.

“During the early years it was critical to have the support of institutions like UNTHSC and the accelerator labs to be able to move the project forward,” Guillem said. “To this day, we continue to collaborate with labs and rely on their equipment and expertise to address various technical topics.”

From the start, ZS Pharma had all the making of a biotech superstar. Founded in 2008, it debuted on Wall Street as the first biotech IPO in Texas since 2000. Its drug, called ZS-9, has been on the fast track from the start.

Multiple clinical trials have shown the effectiveness of the drug, which is expected to hit the market in 2016. It treats hyperkalemia, a potentially life-threatening disease caused by excess potassium. About one in 200,000 people have the condition, which often affects people with chronic kidney disease and chronic heart failure.

Since 2006, UNT Health Science Center’s Office of Research Development and Commercialization and TECH Fort Worth, a non-profit technology incubator, have worked in partnership to bring new technologies to the market.

Firms get a boost from the UNTHSC Accelerator Lab Program along with the Executives-in-Residence, who act as mentors and offer advice from their years of experience in the pharmaceutical industry.

Taking research to the marketplace can be an arduous process. Playing a part in getting this drug on the path to patients has been rewarding for everyone involved , said Lawrence “Joe” Allred, Associate Vice President for Research and Innovation at UNTHSC.

“We can rightfully take pride in ZS Pharma’s success as a graduation of incubation in our Accelerator Labs,” he said.

Recent News

Eun-Young Mun
  • Our People
|Jun 16, 2025

Dr. Eun-Young Mun receives national award for advancing prevention science

  Eun-Young Mun, PhD, a regents professor and associate dean for Research and Innovation at The University of North Texas Health Science Center of Fort Worth’s College of Public Health, has received the Nan Tobler Award at the 33rd annual meeting of the Society for Prevention Research....
Dr. John Licciardone
  • Research
|Jun 12, 2025

Long-term study shows better chronic pain outcomes in patients treated by osteopathic physicians

The first long-term study involving three years of follow-up of osteopathic medical care for chronic pain has been published in the Journal of Osteopathic Medicine. The research team was led by Dr. John Licciardone, executive director of the Osteopathic Research Center and regents professor at T...
Dsc01266
  • Community
|Jun 12, 2025

Legacy Writers: TCOM students bring life stories to the final chapter

When Azelia Lau arrived at the Texas College of Osteopathic Medicine at The University of North Texas Health Science Center at Fort Worth, she brought more than a passion for psychiatry. She also carried a long-held idea inspired by an undergraduate program she never got to join. Now a third-...
Lillee Smith Gelinas 666 X 750
  • Research
|Jun 5, 2025

TCOM course linked to higher patient safety awareness knowledge and residency readiness

The Texas College of Osteopathic Medicine at The University of North Texas Health Science Center at Fort Worth is the first medical school in the country to require a patient safety course that prepares students for the Certified Professional in Patient Safety credential — and a new study publishe...